ViiV unveils emotional challenges related to HIV ART treatment

Pharmaceutical Technology | October 04, 2019

ViiV unveils emotional challenges related to HIV ART treatment
GSK’s ViiV Healthcare has presented results from its Positive Perspectives study examining the emotional challenges and burden of human immunodeficiency virus (HIV) antiretroviral therapy (ART) on people living with the condition. The study found that despite 87% of participants currently in treatment being satisfied with their present ART, there are still emotional challenges associated with the daily regimen of ART, with 66% saying taking daily ART was a constant reminder of their HIV status. Emotional challenges were particularly noteworthy for younger patients and those recently diagnosed. These groups reported more frequent concealment of medications – only 37% of the general group reported frequent concealing of medication, compared to 52% of both younger patients and those recently diagnosed. Younger patients and recently diagnosed patients also reported heightened stress and pressure from taking medications at the right time every day. The Positive Perspectives study recorded 30% of the general survey respondents felt stress and pressure from taking HIV medication at the right time every day, this figure grew to 37% for younger patients and 41% of those who were recently diagnosed with HIV.

Spotlight

The pharmaceutical industry is unique with its extensive regulations. Decisions concerning quality assurance are usually made on the basis of regulatory requirements and guidelines. Quality control takes a central role in the pharmaceutical industry. In addition to being robust and reliable, the means of quality control therefore must be maximally efficient. Timesaving secondary methods have therefore come into the focus of both the pharmeceutical industry and regulatory authorities.

Spotlight

The pharmaceutical industry is unique with its extensive regulations. Decisions concerning quality assurance are usually made on the basis of regulatory requirements and guidelines. Quality control takes a central role in the pharmaceutical industry. In addition to being robust and reliable, the means of quality control therefore must be maximally efficient. Timesaving secondary methods have therefore come into the focus of both the pharmeceutical industry and regulatory authorities.

Related News

Top U.S. health officials self-quarantine after COVID-19 cases in White House

Fiercepharma | May 11, 2020

Welcome to the FiercePharma political roundup, where each Monday we’ll highlight developments in Washington, D.C., and elsewhere that could affect drug pricing and how drugmakers operate. As many businesses in America take steps toward carefully reopening, top U.S. officials guiding the pandemic response are dealing with a COVID-19 outbreak in the country's most high-profile workplace—the White House. After a White House staffer tested positive for COVID-19, FDA Commissioner Stephen Hahn, M.D.; National Institute of Allergy and Infectious Diseases Director Anthony Fauci, M.D.; and Centers for Disease Control and Prevention Director Robert Redfield, M.D., are going into partial or full quarantines for two weeks, CNN reports.

Read More

BUSINESS INSIGHTS

Karo Pharma acquires OTC brand portfolio from Teva Pharmaceuticals

Karo Pharma, Teva Pharmaceuticals | February 04, 2021

Karo Pharma Aktiebolag ("Karo") today reports the securing of an OTC brand portfolio containing Flux®, Decubal®, Lactocare®, Apobase®, Dailycare® and Fludent® from Teva Pharmaceuticals (Teva) for an absolute thought of EUR 84m. The exchange moves responsibility for brand portfolio, included Flux®, Decubal®, Lactocare®, Apobase®, Dailycare® and Fludent® from Teva to Karo. The brands created deals barely shy of EUR 35m in 2020 on a worldwide premise. The greater part is created in the Nordic business sectors, including Scandinavia, where the brands as of now are dispersed and showcased by Karo under a 7-year permit arrangement that was endorsed in the spring of 2019. The exchange adds around EUR 4m in net deals from new business sectors outside of Scandinavia of which approx. 80% is in Finland. The exchange disentangles the business set-up and gives Karo control of the resources, in this way preparing for long haul advancement of the brands and the worth chain. As far as monetary effect Karo will acknowledge direct investment funds in year 1 of simply under EUR 5m as expenses to Teva are disposed of. Karo as of now popularizes the items in Scandinavia and has dynamic associations with the agreement manufacturers that supply the brands. Subsequently, restricted added expenses and faculty are needed as an immediate aftereffect of the exchange. "The transaction is in full alignment with our strategy of owning and commercializing strong OTC brands within everyday healthcare. It gives us full global control of a very exciting brand portfolio that we will develop and optimize over the next years. It strengthens our position in the Nordic markets and notably it expands our business in Finland where we did not previously control these brands. Over the next years we shall expand life cycle management opportunities, drive activation across more channels and explore geographical market expansion", says Christoffer Lorenzen, CEO of Karo Pharma. The obtaining is an unadulterated resource bargain. No staff or assembling locales are incorporated, which limits business just as the innovation move chances. The exchange, which is financed with existing money and requires no extra credit facilities, is relied upon to close on April 1. About Karo Pharma Karo Pharma delivers smart choices for everyday healthcare. We own and commercialize branded, original over-the-counter products and prescription medicines. Our products are available in more than 60 countries, with Europe and the Nordic region as our core markets. Karo Pharma is headquartered in Stockholm, Sweden and listed on Nasdaq Stockholm Mid Cap.

Read More

PRACTICE MANAGEMENT

Royalty Pharma Acquires Royalty Interest in ORLADEYO and BCX9930 From BioCryst Pharmaceuticals

Royalty Pharma | December 08, 2020

Royalty Pharma, BioCryst Pharmaceuticals, Inc. what's more, Athyrium Capital Management, LP today declared exchanges adding up to $325 million in financing for BioCryst, with $250 million accessible at shutting, to help the dispatch of ORLADEYO™ (berotralstat) in genetic angioedema (HAE) and the advancement of its oral Factor D inhibitor, BCX9930. Royalty Pharma will furnish BioCryst with a forthright money installment of $125 million and will get eminences of 8.75% on direct yearly net deals of ORLADEYO up to $350 million, 2.75% on deals between $350 million and $550 million, no royalty on deals over $550 million, and a layered level of sublicense income for ORLADEYO in specific domains. Likewise, Royalty Pharma will get a 1.0% royalty on worldwide net deals of BCX9930, whenever affirmed. An asset oversaw by Athyrium Capital Management will give BioCryst a $200 million credit office, of which BioCryst will draw $125 million at shutting. The extra capital will be accessible in two tranches at BioCryst's alternative, after arriving at characterized income achievements. The credit office bears revenue at LIBOR +8.25% (with a LIBOR floor of 1.75%) and is revenue just for the whole five-year term, with all extraordinary head due at development. Also, BioCryst has the choice to pay revenue in-kind for the initial eight fourth of the term, permitting the organization to concede money premium installments until after this period. The organization will be dependent upon a base liquidity contract of $15 million. There are no other monetary agreements except if the third tranche is drawn by BioCryst. BioCryst plans to contribute the joined continues to help the dispatch of ORLADEYO in the U.S. what's more, Europe and to propel the advancement of BCX9930 into clinical preliminaries in various supplement intervened sicknesses. Also, BioCryst will reimburse its current office with MidCap Financial. "We trust ORLADEYO will be a groundbreaking medication and we are eager to cooperate with BioCryst to bring this oral, once-every day medication to HAE patients. In view of the empowering verification of idea information in paroxysmal nighttime hemoglobinuria with BCX9930, we likewise accept this oral Factor D inhibitor offers considerable open doors over different supplement interceded sicknesses," said Pablo Legorreta, Chief Executive Officer of Royalty Pharma. "With a productive R&D ability, long IP on their items and huge close term business openings, BioCryst speaks to the ideal profile Athyrium looks for our speculations and we are eager to add to the organization's future achievement," said Hondo Sen, accomplice at Athyrium Capital Management. "The generous monetary responsibility of extraordinary long haul accomplices like Royalty Pharma and Athyrium Capital Management empowers BioCryst to completely put resources into the dispatch of ORLADEYO and to quicken the advancement of BCX9930 to address a neglected requirement for patients and convey an incentive to investors. We accept the present financing mirrors the subsequent stage in the change of BioCryst," said Jon Stonehouse, Chief Executive Officer of BioCryst. Cowen went about as monetary guide to BioCryst on the exchange. Gibson Dunn went about as lawful consultant to BioCryst. Goodwin Procter, Wolf Greenfield and Maiwald went about as legitimate counsels to Royalty Pharma. Hogan Lovells went about as lawful counselor to Athyrium Capital Management.

Read More